Nkarta, Inc. (NKTX)


+0.02 (+1.20%)
Symbol NKTX
Price $1.69
Beta -0.050
Volume Avg. 0.49M
Market Cap 82.908M
Shares () -
52 Week Range 1.53-14.57
1y Target Est -
DCF Unlevered NKTX DCF ->
DCF Levered NKTX LDCF ->
ROE -34.12% Strong Sell
ROA -28.55% Sell
Operating Margin -
Debt / Equity 28.46% Neutral
P/E -0.65
P/B 0.26 Neutral


Consensus EPS

Upgrades & Downgrades

Latest NKTX news

Mr. Paul J. Hastings
NASDAQ Global Select

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.